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The Resolute Zotarolimus-eluting stent and diabetes mellitusPatients with diabetes mellitus (DM) undergoing percuta-
neous coronary intervention (PCI) often present with more
complex coronary artery disease, leading to increased risks for
restenosis and adverse events.1e4 While drug-eluting stents
(DES) have been recommended for PCI in DM patients, no DES
prior to the Resolute has been specifically indicated by the US
Food and Drug Administration (FDA) for use in this high-risk
population.1. The Resolute Global Clinical Program
The Resolute zotarolimus-eluting stent (ZES) (Medtronic Inc.,
Santa Rosa, California, USA) is a new-generation DES con-
sisting of a thin-strut cobalt alloy baremetal stent coated with
a durable biostable polymer and the cell-cycle inhibitor
zotarolimus. The polymer architecture was engineered to
allow for prolonged elution of zotarolimus for more effective
inhibition of neointimal proliferation.Fig. 1 e The cumulative incidence of target lesion revasculariza
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http://dx.doi.org/10.1016/j.ihj.2012.10.011The safety and effectiveness of the Resolute ZES have been
established in the RESOLUTE Global Clinical Program, which
includes 2 large international trials (1 randomized and 1
single-arm) with minimal exclusion criteria and 3 single-arm
trials with identical on-label inclusion and exclusion
criteria.5 All 5 Resolute trials were designed with similar
endpoints and statistical methodologies, and all required the
same regimen of dual antiplatelet therapy. An ad hoc analysis
has pooled outcomes for the 5130 recipients of the Resolute
ZES in these 5 clinical trials.52. Achievement of the FDA indication for
diabetes
To obtain an indication for DM patients for the Resolute ZES,
discussions with the FDA were initiated over five years ago. A
statistical analysis plan was developed prospectively with the
FDA to compare 1-year target-vessel-failure (TVF) outcomestion at 2 years in the pooled analysis from the RESOLUTE
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a performance goal derived from a meta-analysis of
published literature (which included 6 trials with Cypher
SES and Taxus PES), and pooled data for the Endeavor ZES.
The composite TVF endpoint included cardiac death,
myocardial infarction, and target vessel revascularization
(TVR). At 1 year, the rate of TVF for the 878 noncomplex dia-
betic Resolute patients was 7.8% (upper 95% CI 9.51%), signif-
icantly lower than the performance goal of 14.5% (p ¼ 0.001),
thus supporting the new FDA indication for DM.3. Two-year pooled outcomes encouraging
for diabetics
For the total population of DM patients, 2-year outcomes were
compared with those for 3595 non-DM patients from the
pooled cohort.6 As expected, rates of major adverse cardiac
events were significantly higher in DM patients than in non-
DM patients. However, the 2-year incidence of ARC-defined
definite or probable stent thrombosis was very low regard-
less of the presence or severity of diabetes (0.82% for non-DM
patients, 0.93% for non-insulin-treated DM patients, and
1.79% for insulin-treated DM patients).
When outcomes were analyzed by treatment with insulin,
the incidence of target lesion failure was nearly the same for
non-insulin-treated DM patients versus non-DM patients but
was significantly higher for insulin-treated DM patients (8.4%
for nondiabetics, 8.9% for non-insulin-treated DM patients,
and 16.7% for insulin-treated DM patients).
The accompanying figure (Fig. 1) breaks out the cumulative
incidence for target lesion revascularization by diabetesstatus. The event rates on this important index of DES effec-
tiveness are low out to 2 years, despite the higher risks and
more complex disease presented by DM patients.6r e f e r e n c e s
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